Gadavist (gadobutrol)

2020: The announcement of Gadavist - contrast agent for MRT of heart at elderly patients with a coronary disease

In the middle of August, 2020 the Bayer company provided Gadavist contrast agent (gadobutrol). This the first contrast substance, available in the market, which is officially permitted for MRT of heart at elderly patients with coronary heart disease.

Contrast MRT of heart using a gadobutrol proved the efficiency in two large multicenter clinical trials where participated nearly 1000 adult patients with symptoms of coronary heart disease. In a research such indicators as volume of perfusion of a myocardium at loading were estimated and at rest and late increase in gadolinium and also a possibility of their further use for the therapy choice.

Bayer presented contrast substance, the first at the market, for MRT of heart at elderly people with a coronary disease

Society of application of a cardiovascular magnetic resonance recognizes MRT of heart the main noninvasive tool which provides to doctors the up-to-date and significant information which is directly influencing treatment. Thanks to approval of regulatory bodies doctors had a new noninvasive tool for performing diagnostics of patients worldwide with suspicion of coronary heart disease which is considered one of the most widespread cardiovascular diseases in the world.

Gadavist (gadobutrol) was for the first time approved in the USA in 2011 for application at MRT for adults and children (of 2 years and is more senior) for detection and visualization of sections with the broken hematoencephalic barrier and/or anomalies of vessels of the central nervous system. In 2014 Gadavist began to use for MRT of a breast at adult patients and children under 2 years, and in 2016 it was approved for use with a magnetic and resonant angiography for assessment of atherosclerosis of an aorta or a renal artery at adults and children, including the full-term newborns.^[1]

Notes